# Clinical and Molecular Phenotyping in IBD

> **NCT02694588** · NA · COMPLETED · sponsor: **University Hospital Schleswig-Holstein** · enrollment: 90 (actual)

## Conditions studied

- IBD

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT02694588
- **Lead sponsor:** University Hospital Schleswig-Holstein
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-10
- **Final completion:** 2021-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02694588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02694588, "Clinical and Molecular Phenotyping in IBD". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT02694588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*